| Human immunodeficiency virus I infection
Edurant vs Fuzeon
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Edurant vs Fuzeon with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFuzeon has a higher rate of injection site reactions vs Edurant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fuzeon but not Edurant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Edurant
Fuzeon
At A Glance
Oral
Once daily
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
SC injection
Twice daily
HIV-1 fusion inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 25 mg oral tablet once daily with a meal for patients weighing at least 25 kg. Pediatric patients 2 years and older weighing 14-20 kg receive 12.5 mg (5 x 2.5 mg dispersed tablets); 20-25 kg receive 15 mg (6 x 2.5 mg dispersed tablets). During pregnancy with virologic suppression, 25 mg once daily with a meal. When coadministered with rifabutin, increase to 50 mg (two 25 mg tablets) once daily with a meal.
Human immunodeficiency virus I infection (Adults) 90 mg (1 mL) SC twice daily injected into the upper arm, anterior thigh, or abdomen.
Human immunodeficiency virus I infection (Pediatric, >=11 kg) 2 mg/kg SC twice daily up to a maximum of 90 mg twice daily injected into the upper arm, anterior thigh, or abdomen; adjust dose with weight changes.
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (more than single-dose treatment)
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Known hypersensitivity to enfuvirtide or any excipient of FUZEON
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, rash, dizziness, nausea, abdominal pain, vomiting, fatigue
Serious Skin and hypersensitivity reactions including DRESS, hepatotoxicity, depressive disorders
Postmarketing Nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Most common Local injection site reactions (pain/discomfort, induration, erythema, nodules/cysts, pruritus, ecchymosis), diarrhea, nausea, fatigue, weight decreased, sinusitis, abdominal pain, cough, herpes simplex, appetite decreased, pancreatitis, pneumonia, myalgia
Serious Pneumonia, hypersensitivity reactions, renal failure, Guillain-Barre syndrome, thrombocytopenia, neutropenia, sepsis, toxic hepatitis, unstable angina pectoris
Postmarketing Cutaneous amyloidosis at the injection site
Pharmacology
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
Enfuvirtide is an HIV-1 fusion inhibitor that binds to the first heptad-repeat (HR1) domain of the gp41 subunit of the viral envelope glycoprotein, preventing the conformational changes required for fusion of viral and cellular membranes and thereby blocking HIV-1 entry into CD4+ cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Edurant
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (11/12)
Fuzeon
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (1/12)
UnitedHealthcare
Edurant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Fuzeon
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (2/8) · Qty limit (2/8)
Humana
Edurant
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Fuzeon
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EdurantView full Edurant profile
FuzeonView full Fuzeon profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.